⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27460923 | 0.69 | — | — | |
| SCHEMBL6244 | 0.64 | — | — | |
| SCHEMBL15547958 | 0.64 | TDP1 (0.31) | — | |
| SCHEMBL15547959 | 0.64 | TDP1 (0.31) | — | |
| Formaldehyde SCHEMBL28177163 | 0.62 | — | — | |
| SCHEMBL4402693 | 0.61 | — | — | |
| SCHEMBL2129648 | 0.60 | — | — | |
| SCHEMBL6013507 | 0.60 | — | — | |
| SCHEMBL2150133 | 0.60 | — | — | |
| Ammonia Solution, Strong SCHEMBL22129991 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262209-B2 | Carbonyloxy-cyanomethyl compounds as antiparasitic agents | NOVARTIS ANIMAL HEALTH US, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262209-B2 | Carbonyloxy-cyanomethyl compounds as antiparasitic agents | NOVARTIS ANIMAL HEALTH US, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20040236137-A1 | Organic compounds | NOVARTIS ANIMAL HEALTH US, INC. | 2004-11-25 | — | — | US | disclosed |
| CN-1545500-A | Carbonyloxy-cyanomethyl compounds as antiparasitic agents | 诺瓦提斯公司 | 2004-11-10 | — | — | CN | disclosed |
| EP-1434760-A2 | CARBONYLOXY-CYANOMETHYL COMPOUNDS AS ANTIPARASITIC AGENTS | Novartis AG (CH) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031393-A2 | CARBONYLOXY-CYANOMETHYL COMPOUNDS AS ANTIPARASITIC AGENTS | NOVARTIS AG (CH) | 2003-04-17 | — | — | WO | disclosed |